Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Extract of fresh opium poppy is an investigational herbal preparation derived from the *Papaver somniferum* plant. Developed by researchers at Region Östergötland in Sweden, it is being evaluated for its potential to alleviate symptoms associated with ureteral stents and other urological conditions such as nephrolithiasis and vesicoureteral reflux. The extract contains a complex mixture of opium alkaloids, including morphine, codeine, thebaine, papaverine, and noscapine. These components act primarily as agonists at opioid receptors (mu, kappa, and delta) and as smooth muscle relaxants (via phosphodiesterase inhibition by papaverine). The primary goal of its use in urology is to reduce ureteral spasms and pain following surgical procedures like ureteroscopy or stent placement for renal and ureteral cancers or stones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on extract of fresh opium poppy.